News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
MONTCO Today on MSN9h
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration Nears
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
Merck buys Raleigh pharma company for $10 billion, drawn by new COPD drug
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Freshfields, Latham Guide Merck’s $10 Billion Plan to Buy Verona
Two Big Law firms guided Merck & Co.'s plans to purchase respiratory drugmaker Verona Pharma Plc for around $10 billion.
Two big reasons why buying Verona was crucial for Merck
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...